Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Anika Therapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue $37.9 million, net income ($10.4) million, EPS ($0.71) per share.
- Period
- first quarter ended March 31, 2023
- Revenue
- $37.9 million
- Net income
- ($10.4) million
- EPS
- ($0.71) per share
- Result
- reported results
Exact text from the filing
First Quarter 2023 Financial Summary Revenue in the first quarter of 2023 was $37.9 million, up 3% compared with $36.7 million in the first quarter of 2022. Osteoarthritis (OA) Pain Management 1 revenue of $22.6 million, up 8% Joint Preservation and Restoration revenue of $13.5 million, up 11% Non-Orthopedic 1 revenue of $1.8 million, down 49% Gross margin was 60%, including $1.6 million of non-cash acquisition-related expenses; Adjusted gross margin 2 was 64%. Net loss was ($10.4) million, or ($0.71) per share, which includes the Parcus Medical unitholder arbitration settlement, as well as shareholder activism and other non-recurring corporate costs, compared to net loss of ($2.9) million, or ($0.20) per share, in the prior year period.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Anika Therapeutics, Inc. reported fiscal year 2023 results: revenue between $158 million and $163 million. Guidance reaffirmed.
- Period
- fiscal year 2023
- Revenue
- between $158 million and $163 million
- Guidance
- reaffirmed
- Result
- guidance update
Exact text from the filing
Fiscal 2023 Revenue Outlook The Company continues to expect its overall revenue for fiscal year 2023 to be between $158 million and $163 million, representing growth of 1% to 4% compared to 2022, as growth in OA Pain Management and Joint Preservation and Restoration is offset by lower ancillary Non-Orthopedic revenues*.
View on SEC.gov